Mirogabalin (Daiichi Sankyo) is an oral therapy that preferentially and selectively binds to the α2δ-1 (alpha-2 delta-1) subunit of calcium channels widely found in the nervous system in areas that mediate pain transmission and processing. Ligands for the α2δ-subunit (α2δ-1 and α2δ-2) are thought to exert analgesic effects by reducing Ca2+ influx into neurons throughout the central nervous system via a mechanism not yet fully elucidated. It is hypothesized that a reduction in Ca2+ influx results in a decreased release of excitatory neurotransmitters such as glutamate, norepinephrine, and substance P, which have been implicated in animal models of induced neuropathic pain.
LIST OF FIGURES
9 Figure 1: Mirogabalin for neuropathic pain – SWOT analysis
10 Figure 2: Datamonitor Healthcare’s drug assessment summary of mirogabalin for neuropathic pain
11 Figure 3: Datamonitor Healthcare’s drug assessment summary of mirogabalin for neuropathic pain
13 Figure 4: Mirogabalin sales for neuropathic pain in Japan, 2017–26
LIST OF TABLES
6 Table 1: Mirogabalin drug profile
7 Table 2: Mirogabalin Phase III data in neuropathic pain
9 Table 3: Mirogabalin Phase II data in neuropathic pain
13 Table 4: Mirogabalin sales for neuropathic pain in Japan ($m), 2017–26
This is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.